bluebird bio (NASDAQ:BLUE) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of bluebird bio (NASDAQ:BLUE) in a report published on Sunday. The firm issued a sell rating on the biotechnology company’s stock.

Other equities research analysts also recently issued research reports about the company. Wells Fargo & Company reduced their price target on bluebird bio from $40.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Monday, February 24th. Baird R W downgraded bluebird bio from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 21st. Barclays reduced their price objective on shares of bluebird bio from $40.00 to $8.00 and set an “overweight” rating on the stock in a research note on Monday, March 31st. Finally, JPMorgan Chase & Co. upgraded shares of bluebird bio from an “underweight” rating to a “neutral” rating in a research report on Monday, February 24th. One analyst has rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $44.60.

bluebird bio Stock Performance

NASDAQ BLUE opened at $4.47 on Friday. The firm has a 50-day moving average price of $4.77 and a two-hundred day moving average price of $7.23. bluebird bio has a 12-month low of $3.56 and a 12-month high of $28.60. The company has a market capitalization of $43.76 million, a P/E ratio of -0.12 and a beta of 0.41. The company has a quick ratio of 0.33, a current ratio of 0.51 and a debt-to-equity ratio of 0.37.

Institutional Investors Weigh In On bluebird bio

A number of institutional investors and hedge funds have recently made changes to their positions in BLUE. Verition Fund Management LLC bought a new position in shares of bluebird bio in the 3rd quarter worth $42,000. Captrust Financial Advisors boosted its stake in bluebird bio by 48.2% in the third quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock worth $123,000 after buying an additional 77,293 shares in the last quarter. Barclays PLC grew its position in bluebird bio by 273.7% during the third quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock valued at $130,000 after acquiring an additional 184,605 shares during the last quarter. Regeneron Pharmaceuticals Inc. purchased a new position in shares of bluebird bio during the fourth quarter worth approximately $175,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of bluebird bio by 2,270.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock worth $193,000 after acquiring an additional 355,562 shares during the last quarter. Hedge funds and other institutional investors own 87.43% of the company’s stock.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.